IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), the global leader in precision targeting of PRAME with multiple clinical-stage programs
Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint;
Houston, Texas and Tuebingen, Germany, July 17, 2026 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), the global leader in precision targeting of PRAME with multiple clinical-stage programs
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancerIn head and neck cancer, IMA401 treatment
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective
SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company's first commercial launch planned in 2027Multiple key clinical data sets
Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell
Individual experimental treatment attempt at Hopp Children's Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR provided by
IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor activity in advanced
Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME,
Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily
